stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Vaxart, Inc.

United States · NASDAQ: VXRT · Market cap: · P/E: · P/S:

Vaxart is a clinical-stage biotech company developing oral vaccines, mostly in pill form, to protect people against infectious diseases.

Vaxart is a small biotech company trying to change how vaccines are given. Instead of a shot in the arm, it is developing vaccines people swallow as pills or tablets. The pitch is simple: a pill is easier to take, doesn't need a needle or a trained nurse, and can be shipped and stored without the deep-freeze logistics that make injectable vaccines expensive to deliver.

Vaxart, Inc. (VXRT) Oral recombinant tablet vaccines: line art illustration of A single white round oral vaccine tablet with a subtle scored line
Oral Vaccine Tablet
Vaxart's vaccines are pills you swallow instead of shots.

The science behind it uses a harmless virus as a delivery truck. Vaxart engineers a weakened adenovirus to carry instructions for a piece of a target germ, then puts it in a tablet that dissolves in the gut. The idea is to train the immune system at the body's front door—the mucosal lining of the nose, mouth, and intestines—where many viruses first attack. That's the theory anyway. The company has run early human trials on pill vaccines for norovirus, seasonal flu, and COVID-19, and its lead norovirus program has advanced the furthest. Vaxart is not yet selling a finished product at scale. It makes money mainly through government contracts and grants that fund its research, plus any partnership deals. That means the company burns cash while it runs trials, and its future depends on one of those programs working well enough to win regulatory approval. It's a high-risk, high-reward bet: a tiny company competing in a field dominated by giants like Pfizer and Moderna, where a single trial result can move the stock sharply.


One odd detail worth knowing: Vaxart's COVID-19 pill vaccine never became a commercial product, but news that it might be tested in a government study once sent the stock soaring, and some investors later complained the company hyped the news. That episode captures the reality of this kind of company—real science, real ambition, but also a business that lives or dies on trial results and funding, not on steady sales.

Saved answer · last researched 16 Nov 2026